If you are wondering whether ImmunityBio’s share price still makes sense after its recent run, the key question is how the current market price lines up with the underlying valuation.
The stock last closed at US$6.45, with returns of 16.8% over 7 days, 201.4% over 30 days, 219.3% year to date and 103.5% over 1 year. This naturally raises questions about both upside potential and risk.
Recent news around ImmunityBio has largely focused on its progress in the pharmaceuticals and biotech space and how that relates to its listed status on the Nasdaq under the ticker IBRX. This context, along with market attention on its drug pipeline and regulatory milestones, has helped frame how investors view the recent price moves.
